Metropolis Healthcare share price
NSE: METROPOLISBSE: 542650Healthcare ServicesSmall Cap
Metropolis Healthcare Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2019 · Issue price ₹880
Last close ₹553.85up ₹2.65 (0.48%)BSE ₹554.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹551.20.
29 Oct: open ₹549.50, high ₹558.00, low ₹543.05
52-week range of traded prices to 29 Oct 2026
₹412.25Low, 2 Apr 2026₹609.05High, 30 Jul 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹11,490 Cr557th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 56.99
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 7.59
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.36%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 14.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 18.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 60,88849.0% delivered
About Metropolis Healthcare
Metropolis Healthcare runs a chain of pathology laboratories that test samples for patients and for hospitals, other laboratories, companies, government bodies and clinical research firms.1 It reaches patients across India through its own and franchised collection centres, home visits and digital channels, and also operates in Africa, Southeast Asia and the Middle East.2
Its tests range from routine pathology to molecular, genetic and genomic diagnostics and cancer testing, and it also offers basic radiology such as X-ray and sonography.3 Its menu has more than 4,500 tests and profiles, about 2,200 of them specialty tests in fields such as oncology, neurology, nephrology and allergy.45 It sells bundled illness and wellness test packages under the TruHealth brand.6 It reports a single business segment, pathology services.7
The business was established in 1981 and began as a single laboratory run by Sushil Shah.89 It was incorporated in 2000.10 It has grown partly through about 25 acquisitions, among them Core Diagnostics in Delhi NCR, which strengthened its oncology (cancer testing), and Hitech Diagnostics in southern India.111213
Its promoters are founder Sushil Shah, a non-executive director, and Ameera Shah, the executive chairperson; the promoter group held 48.9% of the shares, as stated in its presentation of 27 Aug 2026.141516 Surendran Chemmenkotil is the managing director.17
Metropolis Healthcare key points
Results
- In the year to Mar 2026, consolidated revenue from operations rose 24% to ₹1,646 crore and EBITDA (earnings before interest, tax, depreciation and amortisation) rose 32% to ₹401 crore, a 24.4% margin.18
- Profit after tax rose 31% to ₹191 crore in the year to Mar 2026; the year-earlier EBITDA and profit included one-time expenses of about ₹21 crore, mainly acquisition costs.19
- In the quarter to Jun 2026, revenue was ₹450 crore, up 17% from a year earlier, and the EBITDA margin was 25.2%, up 210 basis points (hundredths of a percentage point).20
- The company had no loans or non-convertible debentures at 31 Mar 2026.21
Revenue mix
- In the year to Mar 2026, B2C revenue (from patients directly) rose 19% and B2B revenue (from hospitals, laboratories and other institutions) rose 31%, including acquired businesses.22
- In the year to Mar 2026, specialty testing revenue rose 32% and TruHealth revenue 27%, including acquired businesses. TruHealth, the preventive and wellness packages, made up 18% of group revenue.2324
- In the quarter to Jun 2026, B2C revenue grew 18% and specialty revenue grew 17%; revenue from Tier III (smaller) towns rose about 25%.25
- The company said on 27 Aug 2026 that 25% of its business comes from digital initiatives such as its app and website.26
Where revenue comes from
Labs, network and volumes
- At the end of March 2026 the network had 5,026 service touchpoints across more than 750 towns, after about 490 service centres were added during the year.30
- The company has 209 laboratories; tests a local lab cannot run go to a regional reference lab and then to the global reference lab in Mumbai.3132
- About 700 to 750 of its 5,000 centres are company-owned, largely in the top 7 to 8 towns; in smaller towns the centres are run by franchisees.3334
- In the year to Mar 2026, excluding acquired businesses, patient volumes rose 7.5% to 13.5 million and test volumes rose 8.0% to 28.4 million.35
Research and development
- In the year to Mar 2026 the company set up a Centre of Genomics, with laboratories in Mumbai and Gurugram accredited by the College of American Pathologists, and genomics revenue grew 68%.3637
- In the year to Mar 2026 it received its first patent from the Government of India, for a clinician decision support system for tuberculosis.38
What the company expects
- The company said on 27 Aug 2026 that it expects revenue to grow 14% to 15% in the year to Mar 2027, assuming no price increase and excluding acquisitions.3940
- The company said on 27 Aug 2026 that it aims to raise its EBITDA margin from 24.4% in the year to Mar 2026 to 27% to 28% over the next 2 to 3 years, assuming no scheduled price increase and acquired businesses reaching company-level margins.414243
- In its presentation of 27 Aug 2026, the company said it aims to raise specialty testing from about 40% of revenue in the quarter to Jun 2026 to 45%, and TruHealth packages to 25% of revenue, both over 3 years.444546
- The company said on 27 Aug 2026 that it plans to reach 1,000 own centres over 3 years, to raise collection centres per lab from 24 to 35, and to add 100 mini-hubs offering radiology and consultations.474849
Recent events
- On 7 Sep 2026 Metropolis Quality Solutions, the subsidiary set to take over the company's external quality assessment business (testing other labs' accuracy) for up to ₹1.25 crore, signed investor agreements; the company's fully diluted stake is to fall to 54.90% over 5 years.5051
- On 23 Mar 2026 the company allotted 15,54,95,826 bonus shares, 3 new shares for every 1 held.52
- Its subsidiaries acquired DAPIC of Dehradun (23 May 2025) and Scientific Pathology of Agra (16 Jun 2025), and the company acquired Ambika Pathology of Kolhapur (18 Sep 2025); acquired businesses, Core Diagnostics included, were about 8% of group revenue in the year to Mar 2026.535455
Litigation and regulatory matters
- In its filing of 4 Feb 2026, the company said that after income tax searches in November 2022 the department raised a demand of ₹7,306.46 lakh; on rectification, demands for 7 assessment years (tax years) were reduced to ₹3,880 lakh.56
- The first appeals authority allowed most of the company's grounds for all 10 years; the department's appeals to the Income Tax Appellate Tribunal for 2018-19 to 2023-24 were pending. The company carries a provision of ₹1,964.04 lakh against this liability.57
Last updated
All 57 sources, each with its page
- 1. Annual report, 27 Jul 2026, page 14
- 2. Annual report, 27 Jul 2026, page 14
- 3. Annual report, 27 Jul 2026, page 14
- 4. Annual report, 27 Jul 2026, page 34
- 5. Earnings call, 27 Aug 2026, page 8
- 6. Earnings call, 27 Aug 2026, page 12
- 7. Annual report, 27 Jul 2026, page 359
- 8. Annual report, 27 Jul 2026, page 13
- 9. Earnings call, 27 Aug 2026, page 3
- 10. Annual report, 27 Jul 2026, page 82
- 11. Earnings call, 27 Aug 2026, page 19
- 12. Annual report, 27 Jul 2026, page 18
- 13. Annual report, 27 Jul 2026, page 12
- 14. Investor presentation, 27 Aug 2026, page 8
- 15. Annual report, 27 Jul 2026, page 166
- 16. Investor presentation, 27 Aug 2026, page 10
- 17. Annual report, 27 Jul 2026, page 82
- 18. Annual report, 27 Jul 2026, page 93
- 19. Annual report, 27 Jul 2026, page 93
- 20. Investor presentation, 27 Aug 2026, page 23
- 21. Annual report, 27 Jul 2026, page 190
- 22. Annual report, 27 Jul 2026, page 34
- 23. Annual report, 27 Jul 2026, page 34
- 24. Annual report, 27 Jul 2026, page 10
- 25. Investor presentation, 27 Aug 2026, page 23
- 26. Earnings call, 27 Aug 2026, page 13
- 27. Annual report, 27 Jul 2026, page 359
- 28. Earnings call, 27 Aug 2026, page 20
- 29. Annual report, 27 Jul 2026, page 88
- 30. Annual report, 27 Jul 2026, page 93
- 31. Earnings call, 27 Aug 2026, page 3
- 32. Earnings call, 27 Aug 2026, page 30
- 33. Earnings call, 27 Aug 2026, page 14
- 34. Earnings call, 27 Aug 2026, page 28
- 35. Annual report, 27 Jul 2026, page 93
- 36. Annual report, 27 Jul 2026, page 30
- 37. Annual report, 27 Jul 2026, page 34
- 38. Annual report, 27 Jul 2026, page 26
- 39. Investor presentation, 27 Aug 2026, page 23
- 40. Earnings call, 27 Aug 2026, page 22
- 41. Earnings call, 27 Aug 2026, page 22
- 42. Earnings call, 27 Aug 2026, page 23
- 43. Investor presentation, 27 Aug 2026, page 3
- 44. Investor presentation, 27 Aug 2026, page 17
- 45. Investor presentation, 27 Aug 2026, page 16
- 46. Investor presentation, 27 Aug 2026, page 15
- 47. Investor presentation, 27 Aug 2026, page 14
- 48. Earnings call, 27 Aug 2026, page 12
- 49. Investor presentation, 27 Aug 2026, page 15
- 50. Annual report, 27 Jul 2026, page 94
- 51. Exchange filing, 7 Sep 2026, page 2
- 52. Annual report, 27 Jul 2026, page 139
- 53. Annual report, 27 Jul 2026, page 94
- 54. Annual report, 27 Jul 2026, page 93
- 55. Annual report, 27 Jul 2026, page 94
- 56. Exchange filing, 4 Feb 2026, page 4
- 57. Exchange filing, 4 Feb 2026, page 4
Results
Consolidated; ₹ crore.Metropolis Healthcare quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +21.8%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +32.6%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹450 Crup 6.01%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹57 Crup 11.62%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 12.6%
Revenue by quarter
Peak revenue ₹450 Cr, quarter to Jun 2026; lowest ₹323 Cr, quarter to Dec 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 350 | 323 | 345 | 386 | 429 | 406 | 425 | 450 |
| Net profit | 47 | 31 | 29 | 45 | 53 | 42 | 51 | 57 |
| Net margin | 13.4% | 9.8% | 8.5% | 11.7% | 12.3% | 10.4% | 12.0% | 12.6% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,646 Crup 23.64%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹191 Crup 31.38%
- Net margin
- 11.6%
Revenue by year
Peak revenue ₹1,646 Cr, year to Mar 2026; lowest ₹761 Cr, year to Mar 2019
Net profit by year, a loss in red
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 761 | 856 | 998 | 1,228 | 1,148 | 1,208 | 1,331 | 1,646 |
| Net profit | 124 | 128 | 183 | 215 | 143 | 128 | 146 | 191 |
| Net margin | 16.2% | 14.9% | 18.4% | 17.5% | 12.5% | 10.6% | 10.9% | 11.6% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pathology Services, which carries all its revenue.
Valuation
Today, against the company's own history.Metropolis Healthcare PE ratio and valuation
Price to earnings
At or below today's level on 43% of 1,239 trading days over the last 5 years.
LowestHighest
Its median59.26Industry median19.34
Price to book
At or below today's level on 28% of 1,790 trading days since Aug 2019.
LowestHighest
Its median8.84Industry median1.62
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 55% of 1,797 trading days since Jul 2019.
LowestHighest
Its median0.34%Industry median0.38%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +11.4% | +29.9% | −14.6% | 0.5% |
| 3 years | +11.9% | +9.6% | +1.8% | 0.2% |
| 5 years | −4.6% | +0.4% | −5.4% | 0.3% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
71 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 9 of the 27 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 71 funds holding Metropolis Healthcare
- AddedAdded. Funds that held more shares than at the end of the month before.
- 12
- CutCut. Funds that held fewer shares than at the end of the month before.
- 15
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 44
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 1
| Fund | |||
|---|---|---|---|
 HDFC Focused FundHDFC Mutual Fund | 68,00,000 | 1.39% | ₹368.4 Cr |
| HDFC Flexi Cap FundHDFC Mutual Fund | 65,00,000 | 0.32% | ₹352.1 Cr |
 Kotak-Small Cap FundKotak Mahindra Mutual Fund | 63,79,864 | 1.81% | ₹345.6 Cr |
 Franklin India Small Cap FundFranklin Templeton Mutual Fund | 50,24,465 | 1.91% | ₹272.2 Cr |
 Nippon India Small Cap FundNippon India Mutual Fund | 45,81,344 | 0.31% | ₹248.2 Cr |
| Franklin India Opportunities FundFranklin Templeton Mutual Fund | 40,41,445 | 2.29% | ₹218.9 Cr |
| HDFC ELSS - Tax Saver FundHDFC Mutual Fund | 32,00,000 | 1.16% | ₹173.3 Cr |
 Canara Robeco Small Cap FundCanara Robeco Mutual Fund | 30,11,297 | 1.17% | ₹163.1 Cr |
 Aditya Birla Sun Life Flexi Cap FundAditya Birla Sun Life Mutual Fund | 28,00,000 | 0.54% | ₹151.7 Cr |
| HDFC Aggressive Hybrid FundHDFC Mutual Fund | 24,51,504 | 0.63% | ₹132.8 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Metropolis Healthcare insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group0 purchases, 2 salesNo purchase₹118 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹118 Cr
- Others: no market trade · 6 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Metropolis Healthcare competitors and peers
Healthcare Service Provider, 37 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Metropolis Healthcare in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Dr. Lal Path LabsLALPATHLAB | 32,088 | 59.21 | 12.79 | +14.3% | +5.6% | 23.2% | 26.2% | 0.84% |
 Vijaya Diagnostic CentreVIJAYA | 15,081 | 80.44 | 15.76 | +20.2% | +24.9% | 21.4% | 27.8% | 0.14% |
 Thyrocare TechnologiesTHYROCARE | 8,205 | 56.90 | 14.83 | +22.0% | +12.9% | 26.5% | 43.0% | 1.36% |
 Nephrocare Health ServicesNEPHROPLUS | 6,321 | – | 5.66 | – | – | – | – | 0.00% |
 Suraksha DiagnosticSURAKSHA | 1,664 | 46.49 | 6.80 | +23.3% | +8.1% | 15.7% | 24.0% | 0.16% |
 Krsnaa DiagnosticsKRSNAA | 1,615 | 16.57 | 1.65 | +10.2% | +21.5% | 10.5% | 8.0% | 0.40% |
 3B Blackbio Dx3BBLACKBIO | 1,167 | 21.01 | 3.60 | +54.3% | +13.2% | 18.7% | 14.1% | 0.37% |
 Health X PlatformHEALTHX | 888 | – | 1.39 | +28.8% | – | −3.1% | −9.4% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Metropolis Healthcare dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹2.00 a share, in 5 years, the latest the year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 19 May 2026 | Interim | ₹1.00 |
| 11 Nov 2025 | Interim | ₹4.00 |
| 17 Nov 2023 | Interim | ₹4.00 |
| 23 Feb 2023 | Interim | ₹8.00 |
| 21 Feb 2022 | Interim | ₹8.00 |
| 17 Feb 2021 | Interim | ₹8.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Metropolis Healthcare announcements
Oct 2026
14 Oct · General Updates
5 Oct · Updates
Sep 2026
9 Sep · General Updates
7 Sep
Metropolis Healthcare share price by year
Each calendar year to 2025.Metropolis Healthcare share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 482.23 | −7.1% | 559.18 | 372.15 |
| 2024 | 519.16 | +23.7% | 572.14 | 375.95 |
| 2023 | 419.54 | +26.4% | 428.64 | 299.33 |
| 2022 | 331.88 | −61.4% | 864.91 | 320.26 |
| 2021 | 860.23 | +75.4% | 868.68 | 467.34 |
| 2020 | 490.33 | +35.1% | 572.36 | 288.58 |
| 2019 | 362.89 | – | 364.79 | 228.25 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2019 is from its first session, 15 Apr 2019.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 552.00 | 563.40 | 545.20 | 551.20 | 555.57 | 2,06,976 | 46.9% |
| 27 Oct 2026 | 528.25 | 553.00 | 528.20 | 550.50 | 545.34 | 1,57,320 | 59.3% |
| 26 Oct 2026 | 515.55 | 534.95 | 515.55 | 530.00 | 529.19 | 76,330 | 47.4% |
| 23 Oct 2026 | 524.00 | 528.70 | 512.95 | 522.95 | 520.23 | 3,10,247 | 61.6% |
| 22 Oct 2026 | 526.45 | 535.95 | 511.60 | 530.60 | 526.53 | 3,02,320 | 52.4% |
| 21 Oct 2026 | 519.10 | 538.70 | 511.90 | 533.60 | 524.94 | 2,75,250 | 56.1% |
| 19 Oct 2026 | 533.40 | 534.45 | 512.60 | 519.10 | 520.79 | 1,42,673 | 65.3% |
| 16 Oct 2026 | 529.35 | 549.90 | 518.05 | 530.35 | 527.25 | 1,74,773 | 61.4% |
| 15 Oct 2026 | 526.90 | 548.95 | 517.00 | 523.00 | 530.77 | 2,48,408 | 56.3% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 20 Mar 2026 | Bonus | 0.2500 | Holders received 3 bonus shares for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- METROPOLIS
- BSE code
- 542650
- ISIN
- INE112L01020
- Industry
- Healthcare Services
- Website
- www.metropolisindia.com
- CIN
- L73100MH2000PLC192798
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2000
- Registered office
- 4th floor, East Wing, Plot-254 B, Nirlon House, Dr. Annie Besant Road, Worli, Mumbai 400030, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments